They are a revolutionary biotherapeutics company and their mission is to revolutionize autoimmune and allergic disease treatment by resetting the immune system for superior long-term disease remission.
Their two platform drug candidates, ‘1805 and ‘1104, reset the immune system after only a single administration in an unmatched way. They have demonstrated unique efficacy and safety in preclinical and human studies without immune suppression. Given Revolo's disease-agnostic approach, they are uniquely positioned as Revolutionaries in the development of drugs for various autoimmune and allergic diseases.
Copyright © 2023 Stevenage Bioscience Catalyst